Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Cell Mol Biol (Noisy-le-grand) ; 54 Suppl: OL1062-76, 2008 Dec 01.
Article in English | MEDLINE | ID: mdl-19116086

ABSTRACT

The results of publications on liver transplantation were diverse since several years, without model prognosis. The impossibility was due to the international system of measurement. We resorted to vector functions for calculating the ratios of biological values. We studied 2 samples with the same total number (35 patients) in the same conditions. We proposed 2 vector functions of transplants: (alpha)v1 weight/age donor and recipient in proportion to obtain a medium coefficient; (gamma)v2 ratio of biliary volume/700 mL (minimum secretion); beta was the coefficient of ratio ALT/AST (transaminases). After evaluation of 560 observations and mathematical control about 3000 numbers, we compared the samples with 10 parameters without significant difference between variances, means, other values; with consented errors alpha= beta = 0.05; gamma < 10(-7); means of relative errors = +/- 0.03 negligible. The results were verified by diverse tests (standard deviation of differences, chi2-test, relative risk, odds ratio, comparisons of distributions, parent population, equations of normality, partial correlations, partial regression coefficients, multiple regression, coefficient beta. Final results : quantitative prognosis by grading ; right responders to immunosuppressive treatment without complications, RR1 fast response (scores 3.5 ; 4) ; RR2 slow response (scores 2 ; 2.5 ; 3). Partial responders: very slow response (score 2; 2.5; 3) with transitory complications. Those patients were in recovery (81.5c/o). Wrong responders (score 2), 4 deaths (5.55c/o) by ARS; score 2.5, 1 death (1.5 5c/o) by ARS. We subtracted beta from these scores to differentiate them. Non-responders (score 1.5), 2 deaths (35c/o) by ARS.


Subject(s)
Liver Transplantation , Age Factors , Follow-Up Studies , Graft Rejection/prevention & control , Humans , Liver Transplantation/immunology , Liver Transplantation/mortality , Models, Theoretical , Prognosis , Sex Factors , Tissue Donors , Treatment Outcome
2.
J Ethnopharmacol ; 103(3): 319-26, 2006 Feb 20.
Article in English | MEDLINE | ID: mdl-16198079

ABSTRACT

In traditional medicine in Mali, extracts derived from Mitragyna inermis (Willd.) O. Kuntze (Family: Rubiaceae) are commonly used to treat malaria. The antimalarial activity and the lack of genotoxicity in vitro and in vivo have been demonstrated in previous studies. Acute and chronic evaluation of the toxicity of the hydroethanolic extract of Mitragyna inermis leaves was performed in this study, according to the recommendations (cahier de l'Agence no. 3) of the French Drug Office. Two dosages (300 mg/kg and 3 g/kg) were given in one single administration by gavage to male and female rats. No animal died and no behavioral signs of acute toxicity were observed. Chronic toxicity studies over 28 days showed no changes in body weight and no macroscopic abnormality in the 14 organs examined after the animals were sacrificed. With the 3 g/kg/d drug dosage (100-fold higher than those proposed in man), only slight histological abnormalities were observed. Statistically significant differences, compared to control animals, in the weight of some organs and the values of some haematological or biochemical parameters were observed. However, these values always remained in the range given by the breeder for naive animals of the same strain. These investigations thus seemed to indicate the safety of repeated oral administration (up to 3 g/kg/d) of the hydroethanolic extract of Mitragyna inermis leaves, which can therefore be continuously used with safety by the African population in traditional treatment of malaria.


Subject(s)
Antimalarials/pharmacology , Medicine, African Traditional , Mitragyna , Plant Extracts/pharmacology , Animals , Antimalarials/administration & dosage , Antimalarials/toxicity , Female , Intubation, Gastrointestinal , Male , Mali , Plant Extracts/administration & dosage , Plant Extracts/toxicity , Plant Leaves , Rats , Rats, Wistar
3.
Cell Mol Biol (Noisy-le-grand) ; 51 Suppl: OL723-8, 2005 Sep 02.
Article in English | MEDLINE | ID: mdl-16171571

ABSTRACT

The results of the microscopic examinations on 23 paired liver biopsies of patients affected by the chronic hepatitis C, were realized successively before and after treatment by interferon alpha during six months. They showed a particular interest in the use of the antibody Anticore. The other antibody Anti C100-3-clone Tordji 32, was partially associated with the Anticore to improve its total number of positive responses by interchanging the loss of 3 wrong positive numbers (-) of the same patients from the Anticore, against earnings of 3 wrong negative numbers (+) for the same patients from the Anti C100-3-clone 32. This operation led to 70% of sensitivity. The results were submitted to mathematical verification and allowed to look for the maximum of the predictive probabilities. As for the other antibody Anti C100-3-Tordji-clone 22, it only used as a witness for some positive values. Moreover, this work brought a practical implementation to solve the problem concerning the indeterminate responses. Elsewhere, it appeared plausible for the Anticore to advance beyond its value, if the improvement of its conditions of realization were requiring. That hope was reasonable since it was yielded from the results of the predictive equations of the likelihood ratios by the logistic regression method which built two mathematical models to comparison for confirmation.


Subject(s)
Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/drug therapy , Hepatocytes/drug effects , Hepatocytes/pathology , Immunohistochemistry/methods , Interferon Type I/therapeutic use , Databases, Factual , Fluorescent Antibody Technique , Hepatitis C Antibodies , Hepatitis C, Chronic/pathology , Hepatocytes/virology , Humans , Likelihood Functions , Models, Biological , Normal Distribution , Recombinant Proteins
4.
Cell Mol Biol (Noisy-le-grand) ; 49(4): 509-14, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12899441

ABSTRACT

To find a prognosis model of human liver transplant, we evaluate 62 surgical biopsies for the loss of glycogen and its variations in relation to cold ischemia, reperfusion, lobular zonation and donor's ages. We applied univariate, multivariate and discriminant analysis and logistic regression. There was a clear lobular zonation of glycogen during cold ischemia and at reperfusion. During cold ischemia, the mean loss was 48% in periportal zones and 74% in pericentrilobular zones. At reperfusion, it was in the range of 60% in periportal zones and 95% in pericentrilobular zones. It was observed in 64% of the grafts for an ischemia time less than 10 hr and in 82% of the grafts for an ischemia time of 10 hr or more. It was increased by 90% at reperfusion with pericentral predominance. Donors' age was an aggravating factor of glycogen loss beyond 28 years of age. In conclusion, in periportal zones, mean global glycogen depletion was about 54% during cold ischemia and reperfusion. It decreased by 90% at reperfusion with pericentral predominance. Logistic regression has allowed modelization of cold ischemia and reperfusion.


Subject(s)
Glycogen/metabolism , Liver Transplantation , Liver/metabolism , Adolescent , Adult , Child , Humans , Immunohistochemistry , Ischemia/metabolism , Liver/blood supply , Middle Aged , Multivariate Analysis , Reperfusion
5.
Eur J Haematol ; 69(3): 152-7, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12406008

ABSTRACT

Reticulated platelet count provides an estimate of thrombopoiesis in the same way as reticulocyte count is a measure of erythropoiesis. We applied thiazole orange (TO) staining, followed by fluorescence-activated flow-cytometric analysis, to platelets in whole-blood samples from normal subjects and 18 aplastic patients after chemotherapy for haematologic malignancies. The percentage of TO-positive platelets in 30 control subjects was 5.7 +/- 2.4% (mean +/- 1 SD), determining the threshold of reticulated platelet positivity as up to 10.5% (mean + 2 SD). In the 18 patients studied, the mean percentage of TO-positive platelets was 4.3 +/- 1.89% during aplasia and 23.3 +/- 9.43% during bone marrow recovery, respectively (P < 0.05). All patients had a percentage of TO-positive platelets of up to 10.5%. In comparison, mean platelet volume during bone marrow recovery increased in 12 cases of the 18 patients studied. We conclude that flow cytometric analysis of reticulated platelets is a sensitive and specific test for evaluating thrombopoiesis recovery during aplastic chemotherapy, and platelet transfusion should be reconsidered in these patients.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Bone Marrow/drug effects , Hematologic Neoplasms/blood , Hematologic Neoplasms/drug therapy , Thrombopoiesis/drug effects , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Blood Platelets/drug effects , Blood Platelets/pathology , Bone Marrow/pathology , Female , Flow Cytometry , Humans , Male , Middle Aged , Platelet Count , Predictive Value of Tests
6.
J Stroke Cerebrovasc Dis ; 10(3): 132-4, 2001.
Article in English | MEDLINE | ID: mdl-17903814

ABSTRACT

The aim of this study was to assess a stroke clinic's performance in the diagnosis of hyperlipidemia and more specifically to evaluate the effectiveness of statins in patients with cerebrovascular disease not enrolled in a research study. The records of 370 consecutive patients seen at a stroke clinic over a 4-year period were reviewed, and information regarding neurologic diagnosis, lipid profile, and use and type of cholesterol-lowering medication was abstracted. Hyperlipidemia was defined as a total cholesterol level equal to or more than 200 mg/dL. Forty-eight patients meeting specific criteria were further analyzed to monitor the effects of statins. Cholesterol testing was obtained in 324 patients (88%) and 178 (55%) were hyperlipidemic, but only 86 (48%) patients received treatment. The mean cholesterol level of the 48 patients dropped from 246.2 mg/dL to 197.1 mg/dL (P < .0001) after the initiation of statin therapy, and significant reductions were present in subgroups with pretreatment levels of 200 to 249 mg/dL and 250 to 299 mg/dL. Of the 21 patients with repeated cholesterol testing more than 6 months after the first posttreatment test, only 11 (52%) maintained a level below 200 mg/dL. Effective control of hyperlipidemia can be achieved in patients with cerebrovascular disease, but not all are adequately tested or treated. Improved physician awareness and more effective health care delivery systems are needed.

7.
Cell Mol Biol (Noisy-le-grand) ; 47 Online Pub: OL167-71, 2001.
Article in English | MEDLINE | ID: mdl-11936864

ABSTRACT

The purpose of this study was to localize HCV RNA in formalin-fixed paraffin-embedded liver biopsies of 15 patients with chronic hepatitis C using in situ RT-PCR method. The results were compared to serum and tissue extract analysis of HCV RNA. HCV RNA was detected in 80% of the sera tested, in 40% of the corresponding hepatic tissue extract and in 60% of the tissue sections tested by in situ RT-PCR. Compared to the serum positive cases, 67% of the cases were positive with in situ RT-PCR and 41% were positive with tissue extract detection. 50% of the cases in situ RT-PCR positive were also positive with tissue extract detection. These results underlined the complementarity of the different methods of viral detection for the precise diagnosis of hepatitis C.


Subject(s)
Hepacivirus/genetics , Hepacivirus/isolation & purification , Hepatitis C, Chronic/virology , RNA, Viral/genetics , RNA, Viral/isolation & purification , Formaldehyde , Hepatitis C, Chronic/diagnosis , Humans , Liver/virology , Paraffin , RNA, Viral/blood , Reverse Transcriptase Polymerase Chain Reaction , Tissue Embedding , Tissue Fixation , Virology/methods
8.
Clin Appl Thromb Hemost ; 6(4): 187-9, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11030522

ABSTRACT

There is no consensus concerning thromboembolic prophylaxis in high-risk pregnant women with a previous history of heparin-induced thrombocytopenia. An alternative anticoagulant therapy is danaparoïd, whereas unfractioned and low-molecular-weight heparin therapy is contraindicated. We report a case of successful thrombosis prophylaxis using danaparoïd in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia during a previous pregnancy and Widal's disease.


Subject(s)
Chondroitin Sulfates/administration & dosage , Dermatan Sulfate/administration & dosage , Heparitin Sulfate/administration & dosage , Pregnancy Complications, Hematologic/drug therapy , Thromboembolism/prevention & control , Adult , Anticoagulants/administration & dosage , Aspirin/adverse effects , Asthma/chemically induced , Asthma/complications , Cephalosporins/adverse effects , Drug Combinations , Drug Hypersensitivity , Female , Heparin/adverse effects , Heparinoids/administration & dosage , Humans , Pregnancy , Pregnancy Complications, Hematologic/blood , Risk Factors , Thrombocytopenia/blood , Thrombocytopenia/chemically induced , Thrombocytopenia/complications , Thromboembolism/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...